Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alphapinen added to quadruple therapy for Helicobacter pylori eradication
IRCT20121021011192N15Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha-pinene in Helicobacter pylori infection (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Eradication of Helicobacter pylori rate. Started Jul 2023; status: completed.
02
Drugs
alpha-pinene
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20121021011192N15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20121021011192N15.